TALAPRO-3
06 Dec 2021
TALAPRO-3
NCT04821622
A Phase 3, Randomized, Double-Blind Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer.
Pfizer
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2021-05-12 |
Anticipated End Date | 2027-04-10 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6410 |
Principal Investigator | Dr Yoko Tomita |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs